Discover a novel non-narcotic weight loss therapeutic, H4CBD, that promotes visceral fat loss and improves glucose response without relying on caloric restriction. Ideal for development as a drug or wellness product.
Introducing H4CBD, a groundbreaking synthetic pseudocannabinoid designed to tackle weight loss and metabolic syndrome without the need for caloric intake reduction. This non-narcotic and non-controlled compound has shown remarkable potential in obese rat models, resulting in significant losses in visceral adiposity and improvements in glucose response. With its ability to function independently of insulin signaling alterations, H4CBD offers a promising alternative to traditional weight loss methods.
H4CBD targets metabolic syndrome by:
This therapeutic is administered orally and has demonstrated efficacy over a four-week period in animal models, paving the way for its potential as a pharmaceutical or wellness application.
Currently at Technology Readiness Level 4, H4CBD has progressed through validation in laboratory settings. The research team is seeking further funding to advance this promising therapeutic into clinical studies to fully explore its potential impact on human health.
UC Davis is a comprehensive public research university in Northern California, combining a land-grant heritage with an integrated academic health system and a veterinary teaching hospital. Industry engages through co-located clinical and translational facilities in Sacramento, a campus-adjacent research park, pilot-scale food and bioprocessing facilities, and a statewide extension network for field-to-market deployment. Proximity to the Bay Area and California's Central Valley enables rapid collaboration with startups and established enterprises, while corporate relations staff streamline access to faculty, talent, and core labs. Research is supported by competitive federal funding from agencies such as NIH, NSF, USDA, and DOE. A dedicated technology transfer office and venture support programs provide IP management, licensing, and startup formation pathways for industry partnerships.